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Quercetin Ingestion Does Not Alter Cytokine Changes in
Athletes Competing in the Western States Endurance Run
DAVID C. NIEMAN,1 DRU A. HENSON,1 J. MARK DAVIS,2 CHARLES L. DUMKE,1 SARAH J. GROSS,1
D. PAUL JENKINS,1 E. ANGELA MURPHY,2 MARTIN D. CARMICHAEL,2 JOHN C. QUINDRY,1
STEVEN R. McANULTY,1 LISA S. McANULTY,1 ALAN C. UTTER,1 and EUGENE P. MAYER2
ABSTRACT
The purpose of this study was to measure the influence of quercetin on plasma cytokines, leukocyte cytokine
mRNA, and related variables in ultramarathoners competing in the 160-km Western States Endurance Run
(WSER). Sixty-three runners were randomized to quercetin and placebo groups and under double-blinded
methods ingested 1000 mg/day quercetin for 3 weeks before the WSER. Thirty-nine of the 63 subjects (n 
18 for quercetin, n  21 for placebo) finished the race and provided blood samples the morning before the
race and 15–30 min postrace. Significant prerace to postrace WSER increases were measured for nine proin-
flammatory and anti-inflammatory plasma cytokines, cortisol (quercetin  94%, placebo  96%), serum C-
reactive protein (CRP) (mean  SE absolute increase, quercetin  31.8  4.2, placebo  38.2  5.0 mg/L),
and creatine kinase (CK) (quercetin  21,575  3,977, placebo  19,455  3,969 U/L), with no significant
group differences. Interleukin-6 (IL-6) mRNA did not change post-WSER, with a significant decrease mea-
sured for leukocyte IL-8 mRNA (0.21  0.03-fold and 0.25  0.04-fold change from rest, quercetin and
placebo, respectively) and significant increases for IL-1Ra mRNA (1.43  0.18-fold and 1.40  0.16-fold
change, quercetin and placebo, respectively) and IL-10 mRNA (12.9  3.9-fold and 17.2  6.1-fold change,
quercetin and placebo, respectively), with no significant differences between groups. In conclusion, quercetin
ingestion (1 g/day) by ultramarathon athletes for 3 weeks before a competitive 160-km race significantly in-
creased plasma quercetin levels but failed to attenuate muscle damage, inflammation, increases in plasma cy-
tokine and hormone levels, and alterations in leukocyte cytokine mRNA expression.
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INTRODUCTION
INTENSIVE EXERCISE OF LONG DURATION increases blood levelsof multiple cytokines, with most of these exerting anti-in-
flammatory effects.1,2 In previous studies of athletes compet-
ing in the 160-km Western States Endurance Run (WSER), we
have shown that the greatest fold increase is experienced pre-
race to postrace for interleukin-6 (IL-6) (130-fold), followed
by IL-10 (31-fold), granulocyte colony-stimulating factor (G-
CSF) (26-fold), IL-8 (9-fold), IL-1 receptor antagonist (IL-1Ra)
(7-fold), monocyte chemotactic protein-1 (MCP-1) (3-fold),
macrophage inflammatory protein-1 (MIP-1) (2-fold), mac-
rophage migration inhibitory factor-1 (MIF-1) (1.5-fold), and
tumor necrosis factor- (TNF-) (1.3-fold).3–5 Underlying
mechanisms are being explored, but we have shown that ath-
letes with the greatest degree of muscle damage (as measured
by serum creatine kinase [CK]) experience the highest postrace
plasma levels for most of these cytokines.4,5 IL-6, IL-8, IL-1,
and TNF- mRNA content is increased within postexercise
muscle biopsy samples, and blood leukocytes may secrete in-
creased amounts of IL-8, IL-10, and IL-1Ra during sustained
exercise.6–9
Primary signaling mechanisms for cytokine gene expression
during exercise are poorly understood, but recent data suggest
that nitric oxide (NO) production is a key regulator.9 Other po-
tential triggers of cytokine release during extreme exercise in-
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Science, Appalachian State University, Boone, North Carolina.
clude leakage of endoxtoxins (lipopolysaccharide [LPS]) from
the intestines, elevation in catecholamines and cortisol, high
core body temperature, glycogen deficiency and other meta-
bolic demands, and oxidative stress.1–9 Carbohydrate feedings
during intense and prolonged exercise in the fasted state atten-
uate increases in plasma stress hormones and IL-6, IL-10, and
IL-1Ra but have relatively little effect in athletes consuming
prerace meals.6,7 Although still debated in regard to benefit vs.
risk, a reduction in the inflammatory cytokine response to ex-
ercise through nutraceutical or pharmacologic means is a goal
being pursued by several research teams worldwide.
Plants contain thousands of phenolic compounds, including
more than 5000 flavonoids that exhibit strong antioxidant ac-
tivity.10–12 Flavonols are the most widespread flavonoids in
foods, and the most prominent is quercetin.10 The richest food
sources of quercetin are onions, apples, blueberries, curly kale,
tea, and broccoli.11 Total flavonol intake (with quercetin rep-
resenting about 75%) varies from 13 to 64 mg/day depending
on the study sample and the population studied.10 Human sub-
jects can absorb significant amounts of quercetin from food or
supplements, and elimination is quite slow, with a reported half-
life ranging from 11 to 28 h.12,13 Long-term feeding of quercetin
in rats leads to accumulation in several organs, including the
lungs, testes, kidney, heart, liver, thymus, and muscle.14 De-
spite earlier concerns, long-term, high-dose quercetin supple-
mentation in rodents and humans has not been linked to any
adverse effects.15 Epidemiologic studies indicate that higher
compared with lower quercetin intake is associated with re-
duced risk for ischemic heart disease, type 2 diabetes, asthma,
and various types of cancer, including lung cancer, colorectal
cancer, and prostate cancer.16–19
Quercetin is a powerful antioxidant, and in vitro data show
that quercetin in aglycone form has an antioxidant potency that
is approximately 5-fold greater than that of vitamin C.20 In vitro
cell culture studies indicate that quercetin also exerts anti-in-
flammatory effects and inhibits nuclear factor-B (NF-B) sig-
naling in a variety of cells, including macrophages and periph-
eral blood mononuclear cells (PBMCs).20–27 Quercetin acts by
blocking the protein kinase-mediated IB degradation, thereby
preventing NF-B activation.28 NF-B is a central mediator of
immune responses and regulates the expression of genes en-
coding many cytokines, such as IL-1, TNF-, MCP-1, and
MIP-1/.29 NF-B is activated by proinflammatory stimuli,
such as TNF- and LPS, and various stress stimuli, including
elevated hormones, physical stress, and oxidative stress.24,29
Prostaglandin and NO are also involved in inflammation, and
inducible isoforms of nitric oxide synthase (iNOS) and cy-
clooxygenase (COX-2) are responsible for the production of
large amounts of these proinflammatory mediators.28 Several
in vitro studies indicate that quercetin inhibits NO production
and iNOS expression.23,25,28 Thus, inhibition of iNOS by
quercetin may be one of the mechanisms responsible for its anti-
inflammatory effects and may be an important regulatory path-
way during exercise, as shown by Steensberg et al.9
Given quercetin’s antioxidant, anti-inflammatory, and NF-
B and iNOS inhibitory effects, we hypothesized that quercetin
compared with placebo supplementation would attenuate leuko-
cyte mRNA expression for cytokines and diminish postrace
plasma cytokine levels in endurance athletes competing in the
160-km WSER. We designed a randomized, double-blinded,
placebo-controlled study whereby runners registered for the
2006 160-km WSER ingested soft-chew supplements with or
without 1000 mg quercetin for 3 weeks prior to the race event.
Blood samples were collected 1 day prerace and immediately
after completion of the race and analyzed for nine cytokines,
leukocyte cytokine mRNA expression, cortisol, C-reactive pro-
tein (CRP), CK, and various diagnostic chemistries.
MATERIALS AND METHODS
Subjects and race description
Sixty-three experienced male and female ultramarathoners
from the 2006 160-km WSER were recruited and randomized
to quercetin and placebo groups. Thirty-nine of the 63 subjects
(n  18 for quercetin with 14 males and 4 females, n  21 for
placebo with 18 males and 3 females) finished the race and pro-
vided blood samples prerace and postrace. Prior to testing, in-
formed consent was obtained from each subject, and the ex-
perimental procedures were approved by the institutional
review board of Appalachian State University. To enter the
study, subjects must have qualified for the 2006 160-km WSER
(qualification criteria: completed a 160-km trail race or three
80-km races within the cutoff times or raced 80-km in under
11 h or 100-km in under 14 h).
The 160-km WSER is a point-to-point trail run in the Sierra
Nevada Mountains of northern California and is regarded as
one of the most arduous organized running events in the United
States. The race starts at Squaw Valley, California (1890 m al-
titude), and finishes at Auburn, California (366 m). The trail
race course ascends 777 m to Emigrant Pass (2668 m, the high-
est point) within the first 7 km and then passes through remote
and rugged territory to Auburn. The total altitude gain and loss
during the race is 5500 m and 6700 m, respectively. The race
starts at 5:00 AM, and runners must reach the finish line within
30 h to be eligible for an award.
Research design
Following recruitment and randomization, subjects ingested
soft chews with or without 1000 mg/day quercetin using dou-
ble-blinded procedures for 3 weeks before and the morning of
the WSER. This quercetin dosage was based on unpublished
animal data (J. Mark Davis, personal communication). Subjects
in the quercetin group ingested four soft, individually wrapped
chews each day (two prior to breakfast and two prior to din-
ner) that contained 250 mg quercetin, 250 mg vitamin C, 20
mg niacin, and 20 kcal sugars in a carnauba wax and soy lecithin
base colored with FD&C yellow 6 (Nutravail Technologies Inc.,
Chantilly, VA, and Quercegen Pharma, Newton, MA). Placebo
supplements were prepared exactly the same way minus the
quercetin, vitamin C, and niacin. Data from Quercegen Pharma
indicate that the bioavailability of quercetin is enhanced with
vitamin C and niacin, and thus this study tested whether or not
soft chews with or without the combination of quercetin, vita-
min C, and niacin had an influence on the outcome measures.
On race day, subjects ingested all four chews prior to the 5:00
AM start time. During the prerace supplementation period, sub-
jects were instructed to ingest their normal intake of food, bev-
erages, and supplements while avoiding any other supplements
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containing quercetin, with verification by a dietitian following
the race. A 3-day food record was obtained during the 3-week
prerace supplementation period and analyzed using the com-
puterized nutrition software program, Food Processor (ESHA
Research, Salem, OR).
Subjects provided blood samples during registration in
Squaw Valley, held the morning before the race, and 15–30 min
postrace in Auburn. Plasma aliquots were frozen immediately,
transported on dry ice, and then stored at 80°C until analy-
sis. During race registration, body mass was measured, and sub-
jects filled in a questionnaire on basic demographics and train-
ing history. On race day, body mass was measured at the 90-km
aid station (Michigan Bluff, 1220 m) and within 5–15 min post-
race at Auburn. Subjects completed a postrace questionnaire in-
dicating adherence to the research design. Subjects consumed
food and beverages ad libitum during the race.
Plasma quercetin
Total plasma quercetin (quercetin and its primary conjugates)
was measured following solid-phase extraction via reverse-
phase HPLC with UV detection as described by Quercegen
Pharma. This procedure is similar to that previously published
by Ishii et al.30 Quercetin conjugates were hydrolyzed by in-
cubating 250–500 L plasma aliquots with 10 L 10% DL-
dithiothreitol (DTT) solution, 50 L 0.58 M acetic acid, 50 L
of a mixture of -glucuronidase and arylsulfatase, and crude
extract from Helix pomatia (Roche Diagnostics GmbH,
Mannheim, Germany) for 40 min at 37°C. After incubation, 500
L of 0.01M oxalic acid was added, and each sample was vor-
texed and centrifuged for 5 min at 10,000 rpm. Supernatants (1
mL) were then applied to solid-phase extraction cartridges (Oa-
sis HLB 1cc, 30 mg, SPE cartridge) (Waters Corp., Milford,
MA) that were preconditioned with 1 mL methanol (MeOH),
0.5 mL 0.01M oxalic acid, and 1 mL dH2O and drawn through
at a rate of 0.5 mL/min using a vacuum manifold (Waters Corp).
Cartridges were washed with 0.5 mL MeOH  2. Eluant was
collected into 1.5-mL microcentrifuge tubes. DTT (10% solu-
tion, 10 L) was added to the combined eluant, and the sam-
ples were vortexed for 1 min and placed in a vacuum concen-
trator (Savant Speed Vac SC 110, Savant Instruments Inc.,
Farmindale, NY) until MeOH was completely evaporated. The
residue was reconstituted with 150 L MeOH/dH2O (1:1). In-
jections (50 L) were used for HPLC analysis.
Chromatographic analysis was performed using a Waters
Breeze system (Waters Corp.) consisting of a Waters 1525 Bi-
nary HPLC pump, 2487 UV detector, and Symmetry C18 5 m
4.6  150-mm column. The analysis data were acquired and
processed using Breeze software (v3.02). A mixture of ace-
tonitrile with 0.1% formic acid (A) and dH2O with 0.1% formic
acid (B) was used as the mobile phase. The gradient elution
was programmed as follows: 0–1.5 min, 10/90% A/B; 1.5–9.5
min, 40/60% A/B; 9.5-11.5 min, 90/10% A/B; 11.5–15 min,
10/90% A/B. The column temperature was maintained at 30°C.
The flow rate was 1.0 mL/min. Quantification of the quercetin
peak was based on the standard addition method using both
plasma and MeOH, with similar results. Standards and samples
were treated in an identical manner.
Cytokine measurements
Total plasma concentrations of IL-1Ra, IL-6, IL-8, IL-10, 
G-CSF, MCP-1, MIP-1, TNF-, and MIF-1 were determined
using quantitative sandwich ELISA kits provided by R&D Sys-
tems, Inc. (Minneapolis, MN). All samples and provided stan-
dards were analyzed in duplicate. High sensitivity kits were
used to analyze TNF- and prerace samples of IL-6, IL-10, and
G-CSF. The minimum detectable concentration of IL-1Ra was
22 pg  mL1, IL-6 0.70 pg  mL1, IL-6 (high sensitivity)
0.039 pg  mL1, IL-8 3.5 pg  mL1, IL-10 3.9 pg 
mL1, IL-10 (high sensitivity) 0.50 pg  mL1, G-CSF 
20.0 pg  mL1, G-CSF (high sensitivity) 0.80 pg  mL1,
MCP-1 5.0 pg  mL1, MIP-1 11.0 pg  mL1, TNF-
0.106 pg  mL1, and MIF-1 0.017 ng  mL1. To improve
sensitivity in the detection of IL-8, we employed SOFTmax
analysis software (Molecular Devices, Sunnyvale, CA). Preex-
ercise and postexercise samples for the cytokines were analyzed
on the same assay plate to decrease interkit assay variability.
Leukocyte mRNA extraction and cDNA synthesis
The QIAampRNA Blood Mini Kit Protocol (Qiagen, Va-
lencia CA) was used to extract mRNA. From each subject, 3-
mL aliquots of whole blood collected in EDTA were purified
for RNA. Briefly, erythrocytes were selectively lysed, and
leukocytes were recovered by centrifugation. Samples were
briefly centrifuged through a QIAshredder spin column, etha-
nol was added to adjust binding conditions, and the sample was
applied to a QIAamp spin column. RNA was bound to the sil-
ica gel membrane during a brief centrifugation step. Contami-
nants were washed away, and total RNA was eluted in 30 L
RNase-free water.
The extracted RNA (7.5 L of sample) was dissolved in di-
ethylpyrocarbonate-treated water and quantified spectrophoto-
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TABLE 1. SUBJECT CHARACTERISTICS (MEAN  SE)
Variable Quercetin (n  18) Placebo (n  21) p value 
Age, years 44.2  2.0 46.0  2.3 0.575
Running experience, years 13.0  2.3 13.3  1.7 0.780
Ultramarathons raced 39.6  10.6 37.9  6.0 0.988
Training distance, km · wk1 83.4  5.0 75.8  7.1 0.398
Race time, h 26.4  0.7 27.5  0.6 0.237
Body mass, prerace, kg 68.9  2.7 73.9  2.7 0.168
Body mass, midrace, kg 68.9  2.3 73.5  2.7 0.169
Body mass, postrace, kg 68.0  2.3 73.0  2.7 0.140
metrically at 260-nm wavelength. RNA was reverse transcribed
into cDNA in a 50 L reaction volume containing 19.25 L
RNA in RNase-free water, 5 L 10 RT buffer, 11 L 25 mM
MgCl2, 10 L deoxyNTPs mixture, 2.5 L random hexamers,
1 L RNase inhibitor, and 1.25 L multiscribe reverse tran-
scriptase (50 U/L). Reverse transcription was performed at
25°C for 10 min, 37°C for 60 mins, and 95°C for 5 min, fol-
lowed by quick chilling on ice, and stored at 20°C until sub-
sequent amplification.
Quantitative real-time PCR analysis
Quantitative RT-PCR analysis was done as per manufac-
turer’s instructions (Applied Biosystems, Foster City, CA) us-
ing TaqMan Gene Expression Assays. DNA amplification was
carried out in 12.5 Taqman Universal PCR Master Mix (Am-
pliTaq Gold DNA Polymerase, Passive Reference 1, Buffer,
dNTPs, AmpErase UNG), 1 L cDNA, 9 L RNase-free wa-
ter, and 1.25 L 18S primer (VIC) and 1.25 l primer (FAM)
(for endogenous reference and target cytokine) in a final vol-
ume of 25 L/well. Human control RNA (calibrator RNA) was
also used and served as a calibrator for each plate. Samples
were loaded in a MicroAmp 96-well reaction plate. Plates were
run using ABI Sequence Detection System (Applied Biosys-
tems). After 2 min at 50°C and 10 min at 95°C, plates were
coamplified by 50 repeated cycles, of which one cycle consisted
of a 15-sec denaturing step at 95°C and 1-min annealing/ex-
tending step at 60°C. Data was analyzed by ABI software us-
ing the cycle threshold (CT), which is the value calculated and
based on the time (measured by PCR cycle number) at which
the reporter fluorescent emission increases beyond a threshold
level (based on the background fluorescence of the system),31
and it reflects the cycle number at which the cDNA amplifica-
tion is first detected. We have previously reported detailed
methodology concerning the dual amplification technique.6,7
Samples were run in duplicate, and the intraassay and interas-
say coefficients of variation (CVs) were determined to be 1.69%
and 1.65% for the CTs, respectively.
Calculations for relative quantification
Quantification of cytokine gene expression for IL-8, IL-10,
IL-1Ra, and IL-6 was calculated using the CT method as
described by Livak and Schmittgen.32 This method uses a sin-
gle sample, the calibrator sample, for comparison of every un-
known sample’s gene expression. This method of analysis and
quantification has been shown to give similar results to the stan-
dard curve method.31 Briefly, CT (CT(FAM)  CT(VIC))
was calculated for each sample and calibrator. CT (CT(cal-
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FIG. 1. Plasma quercetin in runners before and after a 160-
km race in quercetin (n  18) and placebo (n  20) groups.
Time effect, p  0.001; quercetin/placebo group  time effect,
p  0.001.
TABLE 2. PRERACE AND POSTRACE (160 KM) SERUM GLUCOSE, CORTISOL, C-REACTIVE PROTEIN, CREATINE
KINASE, AND DIAGNOSTIC CHEMISTRIES IN QUERCETIN (n  18) AND PLACEBO (n  21) GROUPS (MEAN  SE)
Time; interaction
Variable Prerace Postrace effects, p value
Glucose, mmol · L1
Quercetin 5.17  0.17 6.49  0.33 0.001; 0.355
Placebo 5.54  0.20 6.38  0.28
Cortisol, nmol · L1
Quercetin 434  34 835  80 0.001; 0.956
Placebo 412  29 806  97
C-reactive protein, mg · L1
Quercetin 0.4  0.1 32.2  4.3 0.001; 0.346
Placebo 0.8  0.2 39.0  5.1
Creatine kinase, U · L1
Quercetin 159  25 21733  3980 0.001; 0.710
Placebo 171  27 19626  3981
Alanine aminotransferase, U · L1
Quercetin 26.1  1.1 132  20 0.001; 0.598
Placebo 26.1  1.9 118  18
Aspartate aminotransferase, U · L1
Quercetin 28.9  1.3 528  75 0.001; 0.937
Placebo 29.6  1.6 519  95
Blood urea nitrogen, mmol · L1
Quercetin 4.7  0.3 11.0  1.0 0.001; 0.888
Placebo 4.8  0.4 10.9  1.0
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ibrator)  CT(sample)) was then calculated for each sample,
and relative quantification was calculated as 2CT. Initial ex-
clusion criteria consisted of FAM CT 	40 and VIC CT 	 23.
Hemoglobin, hematocrit, diagnostic chemistries, 
CRP, CK cortisol
Complete blood counts for hemoglobin and hematocrit were
measured using a Coulter STKS instrument (Coulter Electron-
ics, Inc., Hialeah, FL). Plasma volume changes were estimated
using the method of Dill and Costill.33 The comprehensive di-
agnostic chemistry panel, CRP, and CK were measured in a
clinical laboratory using an LX-20 clinical analyzer (Beckman,
Brea, CA).
Plasma concentrations of cortisol were determined using the
competitive solid-phase 125I radioimmunoassay (RIA) tech-
nique (Diagnostic Products Corporation, Los Angeles, CA) with
cortisol-specific antibody (Ab) coated tubes (Coat-A-Count
tubes). Intraassay (CVintra) and interassay (CVinter) CVs were
4.5% and 5%, respectively. Assay sensitivity was 5.5 nmol/L
(0.2 g/dL).
Delayed onset of muscle soreness (DOMS)
Subjects recorded muscle soreness after the race and during
the week following the race using a 10-point Likert scale.34
Runners were asked to supply a number that best described any
general feeling of painful, sore, aching leg muscles using this
scale: 1 (no soreness), 2.5 (dull, vague ache), 4 (slight sore-
FIG. 2. IL-8 mRNA expression in blood leukocytes from run-
ners before and after a 160-km race in quercetin (n  18) and
placebo (n  20) groups. Values are expressed as a fold change
from rest, with rest equal to 1. Time effect, p  0.001;
quercetin/placebo group  time effect, p  0.437.
ness), 5.5 (more than slight soreness), 7 (sore), 8.5 (very sore),
and 10 (unbearably sore).
Statistical analysis
Data are expressed as mean  SE, and were analyzed using
a 2 (groups)  2 (time points) repeated measures ANOVA.
TABLE 3. PRERACE AND POSTRACE (160 KM) PLASMA CYTOKINE LEVELS IN QUERCETIN
(n  18) AND PLACEBO (n  21) GROUPS (MEAN  SE)
Time; interaction
Variable Prerace Postrace effects, p value
IL-6, pg · ml1
Quercetin 0.9  0.1 90.4  21.0 0.001; 0.340
Placebo 1.2  0.4 66.5  14.6
IL-10, pg · ml1
Quercetin 9.5  0.5 132.1  28.6 0.001; 0.228
Placebo 9.2  0.3 89.3  20.8
G-CSF, pg · ml1
Quercetin 34.6  3.1 264.2  68.8 0.001; 0.908
Placebo 30.8  2.8 246.7  90.3
IL-1Ra, pg · ml1
Quercetin 137  6 1037  228 0.001; 0.769
Placebo 123  9 919  261
IL-8, pg · ml1
Quercetin 4.5  0.2 25.3  3.7 0.001; 0.415
Placebo 5.1  0.3 21.6  3.7
MCP-1, pg · ml1
Quercetin 129  8 529  52 0.001; 0.423
Placebo 122  6 473  36
MIP-1, pg · ml1
Quercetin 35.4  2.8 73.1  10.4 0.001; 0.300
Placebo 33.5  2.8 99.0  22.6
TNF-, pg · ml1
Quercetin 0.93  0.11 1.62  0.12 0.001; 0.287
Placebo 1.15  0.11 2.34  0.42
MIF-1, ng · ml1
Quercetin 5.4  0.5 12.0  1.5 0.001; 0.667
Placebo 4.7  0.3 12.3  1.8
When the interaction effect was significant (p 
 0.05), prerace
to postrace changes were calculated and compared between
quercetin and placebo groups using Student’s t-tests, with sig-
nificance set at p 
 0.05. DOMS data were analyzed using a
2  8 repeated measures ANOVA. When Box’s M suggested
that the assumptions necessary for the univariate approach were
not tenable, the multivariate approach to repeated measures
ANOVA was used (Pillais trace).
RESULTS
Thirty-nine of 63 subjects (n  18 for quercetin, n  21 for
placebo) completed the 160-km race event and adhered to all
aspects of the study design. A poststudy questionnaire revealed
a successful implementation of the double-blinded supplemen-
tation (of quercetin subjects, 22% indicated they were on
quercetin, 17% on placebo, and 61% were not sure, compared
with 38%, 29%, and 33%, respectively, of placebo subjects).
Air temperature was 22°C at the start of the race at 5:00 AM
(Squaw Valley, CA), 38°C by 2:00 PM (Michigan Bluff), 27°C
by 12:00 AM (race finish, Auburn, CA), and 31°C by 11:00 AM.
The humidity ranged from 25% to 58% during the last half of
the race. There were no significant differences in subject char-
acteristics between the quercetin and placebo groups (Table 1).
Male (n  32) and female (n  7) runners did not differ sig-
nificantly in race time (27.0  0.5 h vs. 27.0  1.39 h, respec-
tively, p  0.992) or change in any of the other variables mea-
sured in this study except for those related to body mass and
composition. Thus, male and female runner data were combined
for this analysis.
Plasma volume did not change appreciably and did not dif-
fer significantly between groups (0.3  0.5% and 0.3 
0.4%, respectively, p  0.928), and body mass was maintained
near prerace levels for both groups (Table 1). Three-day food
records prior to the race event indicated no significant differ-
ences in macronutrient intakes between groups, with a mean
energy intake for all subjects combined of 11.0  0.8 MJ 
day1 (2620  184 kcal  day1) and percent of energy intakes
of 51.1  2.3% carbohydrate, 31.5  1.8% fat, and 18.0 
1.2% protein.
After 3 weeks of supplementation, plasma quercetin levels
were 6.6-fold higher in the quercetin compared with the placebo
group and 3.1-fold higher postrace (interaction effect, p 
0.001) (Fig. 1). Prerace to postrace increases in serum glucose,
cortisol, CRP, CK, alanine and asparate aminotransferase, and
blood urea nitrogen did not differ significantly between
quercetin and placebo groups (Table 2). Prerace to postrace in-
creases in nine cytokines listed in Table 3 did not differ sig-
nificantly between quercetin and placebo groups.
Figures 2, 3, 4, and 5 summarize the leukocyte cytokine
mRNA data. Leukocyte IL-8 mRNA decreased significantly
postrace, with no differences between quercetin and placebo
groups (Fig. 2). Leukocyte IL-10 mRNA (Fig. 3) and IL-1Ra
mRNA (Fig. 4) increased significantly postrace, with no group
differences. Leukocyte IL-6 mRNA did not change postrace,
with no group differences (Fig. 5).
Quercetin and placebo groups did not differ in ratings for
DOMS on race day or the week after the race (interaction ef-
fect, p  0.986) (Fig. 6).
DISCUSSION
High-dose quercetin ingestion (1 g/day) by ultramarathon
athletes for 3 weeks significantly increased plasma quercetin
levels but failed to attenuate muscle damage, DOMS, inflam-
mation, substantial increases in plasma cytokine and hormone
levels, and alterations in leukocyte cytokine mRNA expression
following the 160-km WSER.
The athletes consuming quercetin for 3 weeks achieved
plasma quercetin levels that were 6.6-fold greater than those of
athletes randomized to placebo ingestion. On the day of the
race, athletes in the quercetin group consumed 1 g between 4
and 5 AM but did not consume additional quercetin supplements
during the race. Plasma quercetin levels in the quercetin group
fell to 115 g/L after the 160-km race, a concentration similar
to prerace levels in the placebo group. The half-life of quercetin
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FIG. 3. IL-10 mRNA expression in blood leukocytes from
runners before and after a 160-km race in quercetin (n  18)
and placebo (n  20) groups. Values are expressed as a fold
change from rest, with rest equal to 1. Time effect, p  0.001;
quercetin/placebo group  time effect, p  0.568.
FIG. 4. IL-1Ra mRNA expression in blood leukocytes from
runners before and after a 160-km race in quercetin (n  18)
and placebo (n  20) groups. Values are expressed as a fold
change from rest, with rest equal to 1. Time effect, p  0.001;
quercetin/placebo group  time effect, p  0.888.
has been reported to be 11–28 h, and we hypothesized that
plasma quercetin levels would remain high during the race af-
ter 3 weeks of supplementation and a full 1 g quercetin dose
just prior to the start of the race. This is the first study of hu-
man athletes using high-dose quercetin supplements prior to 
ultramarathon competition, and we learned that the plasma
quercetin level fell substantially more than expected. Ingestion
of quercetin supplements throughout the race would have main-
tained plasma quercetin at a higher level, with perhaps differ-
ent outcomes.
The results of this study, however, are consistent with those
of most other investigations that have failed to show that in-
gestion of antioxidants, such as vitamins E and C, has mean-
ingful effects on exercise-induced inflammation, muscle 
damage, increases in plasma cytokines, and immune perturba-
tions.2,35,36 In contrast to our previous findings showing the 
importance of muscle damage, we have been unable to dem-
onstrate that oxidative stress is strongly associated with in-
flammation or cytokine changes in athletes competing in ultra-
marathons.3–5 We had hypothesized that a stronger antioxidant,
such as quercetin, would prove more useful than vitamin C or
vitamin E as a nutritional countermeasure to exercise-induced
cytokine changes for endurance athletes, but our findings were
not supportive.22
In vitro/cell culture data indicate that quercetin in aglycone
form exerts impressive antioxidant and anti-inflammatory ef-
fects and inhibits proinflammatory cytokine production and
gene expression through modulation of NF-B.20–23,28 Avail-
able data demonstrate, however, that quercetin undergoes con-
siderable chemical modification during digestion and absorp-
tion and is metabolized to methylated, glucurono-sulfated
derivates.12,13,22 The quercetin conjugates may have altered bi-
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FIG. 5. IL-6 mRNA expression in blood leukocytes from run-
ners before and after a 160-km race in quercetin (n  18) and
placebo (n  20) groups. Values are expressed as a fold change
from rest, with rest equal to 1. Time effect, p  0.351;
quercetin/placebo group  time effect, p  0.577.
FIG. 6. Delayed onset of muscle soreness (DOMS) in runners on race day and the week following a 160-km race in quercetin
(n  18) and placebo (n  21) groups. Time effect, p  0.001; quercetin/placebo group  time effect, p  0.986. DOMS scale:
1 (no soreness), 2.5 (dull, vague ache), 4 (slight soreness), 5.5 (more than slight soreness), 7 (sore), 8.5 (very sore), and 10 (un-
bearably sore).
ologic properties and potencies when compared with in vitro
quercetin aglycone experiments, but few human data are avail-
able.22,27 Chen et al.22 showed that in contrast to quercetin in
aglycone form, quercetin-3-sulfate had no antioxidant or in-
hibitory effects on LPS-induced and interferon- (IFN-)-in-
duced iNOS gene expression in mouse BV-2 microglia cell cul-
tures. Another factor to consider is that the high quercetin
concentrations used in many cell culture studies may not apply
to the lower plasma concentrations achievable through oral
quercetin supplementation. Nonetheless, epidemiologic studies
indicate that individuals ingesting quercetin from fruits and veg-
etables experience a reduced risk for lung cancer and ischemic
heart disease, with these benefits apparently related to quer-
cetin’s antioxidative and anti-inflammatory capacities. The
high-dose quercetin ingestion in this study and a previous study
in our laboratory failed to counter exercise-induced perturba-
tions in inflammation, plasma cytokines, and oxidative stress.35
It can be argued that the degree of oxidative, inflammatory, and
physiologic stress acutely induced by prolonged and intensive
exertion overwhelms attempts to apply nutritional countermea-
sures and that quercetin ingestion is more effective within the
context of countering the inflammation and oxidative stress re-
lated to chronic disease.
Race time was about 1 h (4%) shorter in the quercetin com-
pared with the placebo group, but this did not achieve statisti-
cal significance. MacRae and Mefferd37 reported that 6 weeks
of antioxidant supplement with quercetin (600 mg/day) by 11
elite male cyclists decreased the time to complete a 30-km time
trial by 3.1%. These authors speculated that the performance
improvement could have been related to quercetin’s effects on
skeletal muscle redox state, reductions in muscle inflammation
and protection of skeletal muscle protein, and facilitation of mo-
tor unit recruitment. Environmental conditions during the 2006
WSER were severe, and other confounding factors during this
difficult and long trail race create a context that is less than
ideal to test quercetin’s potential effects on performance.
Plasma cytokine levels following the 160-km race rose to
levels similar to what we have previously reported.3–5 In a pre-
vious laboratory study during which 12 athletes cycled inten-
sively for 2 h, blood leukocyte mRNA expression for IL-10 in-
creased 2.7-fold, IL-1Ra 2.2-fold, and IL-8 2.4-fold, with little
change in IL-6.8 Following the 160-km WSER, changes in
blood leukocyte mRNA expression were comparable to the lab-
oratory study for IL-1Ra and IL-6, with a much higher and
lower fold change recorded for IL-10 and IL-8, respectively.
These data are difficult to interpret because of the lack of con-
gruence between plasma cytokine levels and blood leukocyte
cytokine mRNA expression.8 Nonetheless, the marked decrease
in leukocyte IL-8 and increase in IL-10 mRNA expression are
notable findings and suggest an attempt by the immune system
to limit polymorphonuclear cell adherence, degranulation, res-
piratory burst activity, and inflammation when the athlete is al-
ready experiencing significant muscle cell damage and oxida-
tive stress.
In conclusion, using randomized, double-blinded procedures,
1 g/day quercetin ingestion for 3 weeks prior to the 160-km
WSER did not counter changes in blood leukocyte cytokine
mRNA or the large increases in inflammation, muscle soreness,
and plasma cytokines experienced by the athletes. We suggest
that quercetin’s failure to exert effects in our human athletes
anticipated from in vitro studies may have been due to several
factors, including quercetin conjugation following ingestion,
the large drop in plasma quercetin levels during the race event,
the overwhelming level of oxidative stress and inflammation
induced by running a competitive 160-km trail race, or the in-
herent lack of association between oxidative stress and exer-
cise-induced cytokine production within the context of extreme
exertion. In a previous study, we showed that quercetin inges-
tion lowered the incidence of upper respiratory tract infection
in athletes following a period of intensified exercise.35
Quercetin’s pronounced antiviral capacities have been linked in
vitro at least in part to quercetin methylated conjugates. These
are common quercetin metabolites in humans, thus providing a
physiologic rationale for our finding.38 Only a few in vitro stud-
ies have tested quercetin’s impressive antioxidant and anti-in-
flammatory effects using physiologically relevant metabolites,
and this research is needed to test the value of quercetin sup-
plementation for endurance athletes beyond the disease reduc-
tion benefits shown by epidemiologic research.
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